Terms: = Germ cell tumor AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
28 results:
1. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
2. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.
Wang C; Liu X; Guo S
BMC Complement Med Ther; 2023 Oct; 23(1):371. PubMed ID: 37865727
[TBL] [Abstract] [Full Text] [Related]
3. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
[TBL] [Abstract] [Full Text] [Related]
4. Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma.
Li H; He J; Li M; Li K; Pu X; Guo Y
Front Immunol; 2022; 13():1027631. PubMed ID: 36532035
[TBL] [Abstract] [Full Text] [Related]
5. LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-mek1/2-ERK1/2 pathway.
Wei C; Zhang X; Peng D; Zhang X; Guo H; Lu Y; Luo L; Wang B; Li Z; He Y; Du X; Zhang S; Liang H; Li S; Wang S; Han L; Zhang J
Cell Death Dis; 2022 Nov; 13(11):942. PubMed ID: 36351895
[TBL] [Abstract] [Full Text] [Related]
6. FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract] [Full Text] [Related]
7. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
[TBL] [Abstract] [Full Text] [Related]
8. MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid tumors.
Shahab S; Rubens J; Kaur H; Sweeney H; Eberhart CG; Raabe EH
J Neuropathol Exp Neurol; 2020 Jul; 79(7):746-753. PubMed ID: 32472116
[TBL] [Abstract] [Full Text] [Related]
9. miRNA-183∼96∼182 regulates melanogenesis, cell proliferation and migration in B16 cells.
Du B; Liu X; Khan A; Wan S; Guo X; Xue J; Fan R
Acta Histochem; 2020 Apr; 122(3):151508. PubMed ID: 31980137
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract] [Full Text] [Related]
11. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract] [Full Text] [Related]
12. mek1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.
Yang L; Ding JL
Front Immunol; 2019; 10():2020. PubMed ID: 31507609
[TBL] [Abstract] [Full Text] [Related]
13. Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival.
Mahapatra L; Andruska N; Mao C; Gruber SB; Johnson TM; Fullen DR; Raskin L; Shapiro DJ
Melanoma Res; 2019 Oct; 29(5):539-543. PubMed ID: 30543563
[TBL] [Abstract] [Full Text] [Related]
14. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
[TBL] [Abstract] [Full Text] [Related]
15. LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma.
Vieira GC; Chockalingam S; Melegh Z; Greenhough A; Malik S; Szemes M; Park JH; Kaidi A; Zhou L; Catchpoole D; Morgan R; Bates DO; Gabb PD; Malik K
Oncotarget; 2015 Nov; 6(37):40053-67. PubMed ID: 26517508
[TBL] [Abstract] [Full Text] [Related]
16. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract] [Full Text] [Related]
17. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract] [Full Text] [Related]
18. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma.
Hsieh R; Nico MM; Coutinho-Camillo CM; Buim ME; Sangueza M; Lourenço SV
Am J Dermatopathol; 2013 Apr; 35(2):167-75. PubMed ID: 23000904
[TBL] [Abstract] [Full Text] [Related]
19. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract] [Full Text] [Related]
20. Favourable prognosis in medulloblastoma with extensive nodularity is associated with mitogen-activated protein kinase upregulation.
Jóźwiak J; Sontowska I; Bikowska B; Grajkowska W; Galus R; Roszkowski M
Folia Neuropathol; 2011; 49(4):257-61. PubMed ID: 22212915
[TBL] [Abstract] [Full Text] [Related]
[Next]
